Menu

Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials | TechCrunch
📰

Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials | TechCrunch

TechCrunch·Ram Iyer·32 minutes ago
#dn5lK4bA
Reading 0:00
15s threshold

In Brief

Posted:

6:50 AM PST · November 17, 2026

Image Credits: Jose Sarmento Matos/Bloomberg / Getty Images

Isomorphic Labs , the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials.

The funding was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other investors also participating. All of the company’s existing backers, including Alphabet’s venture divisions GV and Capita G, Thrive Capital, MGX, Temasek, and the U.K. Sovereign AI Fund, also invested.

Isomorphic Labs builds an AI drug-design engine that uses a slew of simulation AI models that explore various areas of chemistry to help the company design drugs. The company, whose work builds on DeepMind’s breakthrough AlphaFold protein-folding AI model , said its program has yielded “positive preclinical results” in oncology and immunology.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.